Logo

The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer

Share this
HUTCHMED

The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer

Shots:

  • The NMPA has accepted & granted priority review to the NDA of fruquintinib + sintilimab for treating advanced endometrial cancer patients having pMMR1 or non-MSI-H2 tumors, were failed on previous systemic therapy & are not eligible for curative surgery or radiation
  • The NDA was based on the endometrial cancer registration arm, FRUSICA-1, of P-II study assessing fruquintinib + sintilimab to treat endometrial cancer patients having disease recurrence & progression or intolerable toxicity due to Pt-based doublet CT with the 1EP as ORR & the 2EPs as DCR, DoR, PFS, OS & PK characteristics
  • Additionally, in Jul 2023, the NMPA granted BTD to fruquintinib combined with sintilimab for the same indication

Ref: HUTCHMED | Image: HUTCHMED

Related News:- HUTCHMED Receives the Pharmacy and Poisons Board of Hong Kong’s Approval for Elunate (fruquintinib) to Treat Metastatic Colorectal Cancer (CRC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions